Back to results
US 2002/0119474 A1Published application
Diagnosing asthma patients predisposed to adverse beta-agonist reactions
OwnerJeffrey M. Drazen, Vern Chinchilli +5inventors
InventorsJeffrey M. Drazen, Vern Chinchilli, Richard Martin, Robert Lemanske, Jean G. Ford, James E. Fish, Homer Boushey
Life of this patent
Estimating the term…
Abstract
The present invention provides a novel method for identifying individuals who are likely to have negative responses to regular administration of β-agonists. The invention also provides kits useful for this purpose.
Claims7
A kit comprising:
- a first set of primers selected so that one of the primers hybridizes to a first portion of a human β2-adrenergic receptor gene, which first portion includes a sequence encoding position 16 of said human β2-adrenergic receptor, in such a manner that, when used in a polymerase chain reaction, said second set of primers amplifies said portion when position 16 is Arg but not when position 16 is Gly;
- and
- a second set of primers selected so that one of the primers hybridizes to a first portion of a human β2-adrenergic receptor gene in such a manner that, when used in a polymerase chain reaction, said second set of primers amplifies said portion when position 16 is Gly but not when position 16 is Arg,
- said first and second sets of primers being provided together in a container.
1 more element
A kit comprising:
- a primer set selected to hybridize to a human β2-adrenergic receptor gene in such a manner that, when used in a polymerase chain reaction, the primer set amplifies a portion of said human β2-adrenergic receptor gene, which portion includes a sequence encoding human β2-adrenergic receptor residue 16;
- and
- reagents for determining the nucleotide sequence of said amplified portion, said primer set and reagents being arranged together in a container.
A kit comprising:
- an oligonucleotide primer that hybridizes to a portion of a human β2-adrenergic receptor gene, which portion includes a sequence encoding residue 16 of the human β2-adrenergic receptor, said oligonucleotide having higher affinity for said portion when said sequence encodes Arg than it has when said sequence encodes Gly;
- and
- an oligonucleotide primer that hybridizes to a portion of a human β2-adrenergic receptor gene, which portion includes a sequence encoding residue 16 of the human β2-adrenergic receptor, said oligonucleotide having higher affinity for said portion when said sequence.
Dependencies are inferred from the claim text.